Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now that the news has sunk in, hopefully real investors will push the penny flippers out of the way this week. Lets hope for a positive trend. GLTA
I believe that we will be in for a big (positive) surprise come 03 December during the Conference call. GLTA
Technical Summary (scroll down). https://www.investing.com/equities/generex-biotech-corp
Great movement today. $23 is looking close on L2.
Technical indicators are all Buys. https://www.investing.com/equities/generex-biotech-corp
Thank you very much for the education. It is greatly appreciated.
Maybe you can educate me. Do you think that the stock has a potential dip due to the 20:1 issue. |I have never been part of something like this. I was the one who got the 500 shares at $8.92 this week. So I will be sitting with 10K shares after everything is complete. I'm very happy but don't want to see a major dip. What do you think?
Your lucky. Many have been stuck for a very long time (I was also one of them) had to take a loss. I hope it works out for those that are still hanging in there.
Yes it is however, you are dreaming if you think that this is going to have massive movement. Look at the broken timelines. How long has your money been sitting here and doing nothing? The smart play is to move on as I did. GLTY
You are correct. The train is taking off. Many people don't know about this golden opportunity. We are in a great spot. The real Whales have not shown up yet and we are still making wonderful progress.
3.5 Million in debt. Stay away from this stock. Going Current isn't going to help this disaster of a so called Company.
2. Going Concern
NSL’s financial statements are prepared using Generally Accepted Accounting Principles applicable to a
going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of
business. However, NSL has generated minimal revenue and accumulated significant losses since
inception. As of September 30, 2018, company has accumulated a deficit of $2,533,041 and a working
capital deficit of $1,080,821. All of these items raise substantial doubt about its ability to continue as a
going concern. Management’s plans with respect to alleviating the adverse financial conditions that caused
management to express substantial doubt about the NSL’s ability to continue as a going concern are as
follows:
In order to fund the start-up of operations during the period ended September 30, 2018, management plans
to enter into several financing transactions and try to raise funds. The continuation of the Company as a
going concern is dependent upon its ability to generating profitable operations that produce positive cash
flows. If the Company is not successful, it may be forced to raise additional debt or equity financing.
There can be no assurance that the Company will be able to achieve its business plans, raise any more
required capital or secure the financing necessary to achieve its current operating plan. The ability of the
Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan
described in the preceding paragraph and eventually attain profitable operations. The accompanying
financial statements do not include any adjustments that might be necessary if the Company is unable to
continue as a going concern.
Remember we have a $40 price target. Well on our way....
Check out GNBT for extra action.
8.24 now. Winner....
The run has begun!!!!!!!!
I'm Long. Hoping for the best for all.
L2 shifted nicely. May see a positive reversal.
News!!!
MIRAMAR, Fla.--(BUSINESS WIRE)--November 14, 2018--
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has revised the record and payment dates for the previously announced 20:1 common stock dividend.
The Record Date for the determination of the holders of the Company's common stock entitled to participate in the Company's 20:1 common stock dividend will now be Tuesday, November 20, 2018. The dividend Payment Date will be Friday, November 30, 2018.
The Company believes that the ex-dividend date will be Monday, December 3, 2018 by application of FINRA Uniform Practice Code section 11140(b)(2) because the dividend is greater than 25 percent of the value of the Company's common stock. In addition, effective September 5, 2017, the U.S. Securities and Exchange Commission shortened the settlement cycle for transactions in U.S. equities from trade date plus three business days (T+3) to T+2 (Rule 15c6-1(a) under the Securities Exchange Act of 1934 (17 CFR 240)). Common stock acquired in trades settled prior to the ex-dividend date will be entitled to receive the dividend.
If shareholders of record sell stock after the record date but before the ex-dividend date, their shares will be sold with a "due bill" book entry which will denote that, although the Company will pay the dividend to the stockholder's account, the stockholder's account must relinquish the amount of that dividend over to the buyer of the stock. Conversely, if stock is purchased after the record date but the trade settles before the ex-dividend date, the buyer will be entitled to the dividend and will receive it via the due bill process.
The stock dividend will result in 20 shares of common stock paid for every share of common stock owned.
Generex President & Chief Executive Officer Joseph Moscato stated: "I am pleased that we now have definitive dates for our common stock dividend and can now move forward with this part of our plan to reward our stockholders for their patience as we've reorganized Generex and paved the way for us to create value for our stockholders as we continue to build value in our Company."
This press release does not constitute legal advice. Investors are encouraged to solicit independent legal advice and to consult their independent investment brokerage firms as to record, payment, and ex-dividend dates and the application thereof to trades in the Company's common stock in the context of the stock dividend.
Reverse Splits are never a fun process. I'm trying to remain optimistic. I hope that we all get a surprise of positive movement.
I anticipate the official revenue PR to come out just before the bell or a little bit after. The October 16th PR stated that its going to be today. Lets hope it happens.
Current Share Structure
https://www.otcmarkets.com/stock/GNBT/security
First resistance has been broken. The second resistance is $15.96
L2 is looking good for an afternoon reversal.
Great movement today. I got very lucky with my $8.92 entry today. I hope everyone gets good returns with the reversal. GLTA
Cannabinoids And Other Pain Relief Options
ACCESSWIRE - Mon Nov 12, 11:35AM CST
HENDERSON, NV / ACCESSWIRE / November 12, 2018 / Opioids are a scourge companies across several sectors are looking to help eradicate. Pain relief options are popping up left and right in an attempt to replace the opioids doctors have been prescribing for years. Below are several companies that could be the solution to this major problem
The first on our list is Endonovo Therapeutics, Inc. (ENDV). ENDV has an extremely promising non-invasive pain reduction treatment therapy called SofPulse that could be the answer for larger companies looking at opioid alternative pain relief solutions.
ENDV recently concluded a study on SofPulse's effectiveness in treating nonalcoholic steatohepatitis (NASH). One to 2 weeks of treatment with SofPulse appeared to counteract several of the disease signs associated with NASH-associated liver damage.
Male mice, 8 weeks old were placed on an MCD diet (methionine-choline deficient diet) for either 7 or 14 days. Feeding mice a diet deficient in methionine and choline is a commonly used mouse model to study the inflammation and hepatic ballooning associated with NASH. To determine if Endonovo's non-invasive medical device could ameliorate the manifestations of a NASH induced diet, mice were exposed to either a proprietary electroceutical therapy system or a sham system during the duration of the MCD diet.
ENDV would be a great place to start if you're looking to research potential companies that could be the answer to the opioid crisis.
Companies to put on your radar include: Endonovo Therapeutics, Inc. (ENDV), Aurora Cannabis (NYSE:ACB), Aphria, Inc. (NYSE:APHA), INSYS Therapeutics, Inc. (NASDAQ:INSY), and CV Sciences, Inc. (CVSI).
Endonovo Therapeutics, Inc. (ENDV)
Market Cap: $14.14M Share Price: $0.038
Endonovo Therapeutics, Inc. (ENDV), a commercial-stage developer of Electroceutical™ Therapies, announced a distribution agreement with Magniant, LLC for the distribution of Sofpulse, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling. The agreement with Magniant includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.
Alan Collier, Endonovo Chief Executive Officer, stated, "We are thrilled to partner with Magniant, an established firm with significant health industry experience, in depth knowledge of product launches and, more importantly, relationships with healthcare professionals and facilities throughout the United States. In addition to a professional, accountable team of commission-based representatives, Magniant delivers meaningful senior leadership in the areas of Supply Chain, FP&A, Operations and Logistics, Marketing, and Clinical Business Development. I welcome the opportunity of working with their team and expanding our SofPulse device on a national level."
Aurora Cannabis, Inc. (NYSE:ACB)
Market Cap: $7.19B Share Price: $7.49
Aurora Cannabis Inc. (ACB), just announced the official opening of its latest high-tech cannabis production facility in Lachute, Quebec; the company is calling it "Eau."
At 48,000 square feet, with 11 purpose-built grow rooms, Aurora Eau will produce up to 4,500 kg of high quality cannabis per year, all in a facility with some of the lowest electricity costs in North America. It is designed to grow niche varieties of cannabis for the premium medical and adult consumer use markets in Quebec, Canada and around the world. Eau becomes Aurora's second production facility in Quebec , the first being Aurora Vie, a 40,000 square foot indoor grow facility in Pointe Claire, Quebec .
Aphria, Inc. (NYSE:APHA)
Market Cap: $3.29B Share Price: $12.72
Aphria Inc. (APHA) announced an agreement with Rapid Dose Therapeutics Inc. that grants the Company with exclusive global preferred rights to license, manufacture, distribute and sell RDT's QuickStrip™ innovative, proprietary delivery technology for both medical and adult-use cannabis market.
INSYS Therapeutics, Inc. (NASDAQ:INSY)
Market Cap: $605.09M Share Price: $8.15
NSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently reported financial results for its third quarter ended Sept. 30, 2018. The company achieved net revenue of $18.3 million in the third quarter of 2018.
CV Sciences, Inc. (CVSI)
Market Cap: $608.87M Share Price: $6.37
CVSI announced that it will be a Title Sponsor of the 25th anniversary of HIACON Conference on November 2-5, in Los Angeles, California. Produced by the Hemp Industries Association (HIA), HIACON will bring together over 400 attendees (cultivators, stakeholders, buyers), more than 55 speakers and industry thought leaders, and many other hemp and CBD sponsors to the Hilton Los Angeles Airport Hotel.
New News Feed Release
Citron's Left expects Canadian cannabis names to fall
Citron Research's Andrew Left expects Canadian cannabis stocks to blow up in the future.
"When U.S. LPs (companies) go public in the next few years it will make these Canadian companies laughable," Left says.
"The cannabis trade is a perfect trade because the cannabis trade is a nonbranded, no-moat megatrend," he adds.
Left says he has kept his short position in Tilray (TLRY +4.2%) through the recent rally on the expectation that when the IPO lock-up expires the doubled float will force the share price down.
Left has no position in Canopy Growth (CGC -2%).
Related names: OTCPK:MJNA, ACB, GWPH, OTCQB:PHOT, OTCPK:CBIS, APHQF, OTCQX:TRTC, CRON, OTCQX:CANN, OTCPK:ERBB, OTCPK:GRNH, OTCQB:PMCB, OTCQB:CVSI, OTC:FITX, MJ, OTCPK:HEMP, OTCQB:CBDS, OTCPK:BLOZF, OTCQB:KSHB, OTCQB:MSRT OTCQX:SPRWF, OTCPK:AGTK, OTCPK:AMMJ, OTCPK:VAPE, OTCPK:HYYDF, OTCQB:GBLX, OTCQB:AERO, OTCPK:MCOA, OTC:HMLSF
It's just sad to see the Ask being undercut every time for a penny flip.
I agree. $8 is a conservative price however, MM's and penny flippers were definitely holding us down last week. I believe that we will be back in the $5.50 to $6 range early next week. People will regret selling out of fear and before they know it, they will be chasing. GLTA.